From the conversation with your doctor through receiving your COPAXONE® from the pharmacy, we’ll show you how to be proactive about your prescription—and why it’s important.

Are there generics available for COPAXONE®?

Yes. However, if you’re looking for affordable access to your RMS therapy, know that most people taking COPAXONE® 40 mg—more than 70%—pay less than $10 per month out of pocket. Medication costs vary for everyone based on insurance coverage, but to date, over 80% of healthcare plans cover Teva's COPAXONE®.1 Learn how Teva's Shared Solutions® could help.

Take action to ensure you receive COPAXONE® as prescribed, rather than a generic option:

  • Talk to your doctor.

  • Inform the pharmacy.

  • Check the packaging.

Talk to your doctor about your COPAXONE® prescription

  • Download this guide to prepare for the conversation, whether you are new to COPAXONE® or currently taking COPAXONE® to manage your relapsing MS.

  • Ask your doctor to include specific language such as “Dispense As Written (DAW),” “Brand Medically Necessary” or other wording as indicated by your state regulations on all new and refill COPAXONE® prescriptions to ensure you receive your RMS therapy as prescribed.

  • This action helps ensure the pharmacy cannot substitute your COPAXONE® without your doctor’s permission and notice to you.

Inform the pharmacy you wish to receive COPAXONE®:

  • When filling your COPAXONE® prescription for the first time, talk with your pharmacist to request Teva’s COPAXONE® by name and ensure this information is recorded for all future prescriptions and refills.

  • When you receive your prescription, check the package before leaving the pharmacy (or when receiving your prescription by mail) to make sure it is Teva's COPAXONE®.

  • If you did not receive your medication as prescribed, talk to your pharmacist immediately and request Teva's COPAXONE® for all new prescriptions and refills moving forward. Then call your doctor's office to alert your doctor of the substitution.

COPAXONE® (glatiramer acetate injection) 40 mg and 20 mg packaging

Check the packaging to make sure it's COPAXONE®2:

  • Look for the COPAXONE® name on all labeling and the NDC number on the box.

  • Teva's 3-times-a-week COPAXONE® 40 mg can be identified by the blue plunger.

COPAXONE® (glatiramer acetate injection) 40 mg  blue plunger COPAXONE® (glatiramer acetate injection) 40 mg  blue plunger

How is COPAXONE® made?

Glatiramer acetate injection is a complicated product to manufacture. FDA-approved for over 20 years, Teva uses a controlled process to ensure consistent quality of the product when manufacturing COPAXONE®.2-4

What if I’m switched from COPAXONE® to a generic option by my insurance?

Teva's Shared Solutions® is available at 1-800-887-8100 to answer questions about MS for people who move to a generic glatiramer acetate injection. Note: only people taking Teva's COPAXONE® will continue to receive the full breadth of personalized services that Teva's Shared Solutions® offers.


COPAXONE® (glatiramer acetate injection) is prescription medicine used for the treatment of people with relapsing forms of multiple sclerosis (MS).

Important Safety Information

Do not take COPAXONE® if you are allergic to glatiramer acetate or mannitol.

Some patients report a short-term reaction right after or within minutes after injecting COPAXONE®. This reaction can involve flushing (feeling of warmth and/or redness), chest tightness or pain, fast heart beat, anxiety, and trouble breathing. These symptoms generally appear within seconds to minutes of an injection, last about 15 minutes, and do not require specific treatment. During the postmarketing period, there have been reports of patients with similar symptoms who received emergency medical care. If symptoms become severe, call the emergency phone number in your area. Call your doctor right away if you develop hives, skin rash with irritation, dizziness, sweating, chest pain, trouble breathing, or severe pain at the injection site. If any of the above occurs, do not give yourself any more injections until your doctor tells you to begin again.

Chest pain may occur either as part of the immediate post-injection reaction or on its own. This pain should only last a few minutes. You may experience more than one such episode, usually beginning at least one month after starting treatment. Tell your doctor if you experience chest pain that lasts for a long time or feels very intense.

A permanent indentation under the skin (lipoatrophy or, rarely, necrosis) at the injection site may occur, due to local destruction of fat tissue. Be sure to follow proper injection technique and inform your doctor of any skin changes.

The most common side effects of COPAXONE® include redness, pain, swelling, itching, or a lump at the site of injection, flushing, rash, shortness of breath, and chest pain. These are not all of the possible side effects of COPAXONE®. For a complete list, ask your doctor or pharmacist. Tell your doctor about any side effects you have while taking COPAXONE®.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit or call 1-800-FDA-1088.

Please see full Prescribing Information for Teva's COPAXONE®.


  1. IQVIA Health National Prescription Audit, September 2018. Data proprietary to IQVIA.

  2. COPAXONE® (glatiramer acetate injection) Current Prescribing Information. Teva Neuroscience, Inc.

  3. Johnson KP. Glatiramer acetate and the glatiramoid class of immunomodulator drugs in multiple sclerosis: an update. Expert Opin Drug Metab Toxicol. 2010;6(5):643-660.

  4. Schellekens H, Klinger E, Mühlebach S, Brin J-F, Storm G, Crommelin DJA. The therapeutic equivalence of complex drugs. Regul Toxicol Pharmacol. 2011;59(1):176-183.

Injections for 3-times-a-week COPAXONE® 40 mg must be at least 48 hours apart.

autoject®2 for glass syringe is a registered trademark of Owen Mumford, Ltd. Available by prescription only.
Apple is a registered trademark of Apple Inc. App Store is a service mark of Apple Inc.
Google Play and the Google Play logo are trademarks of Google LLC.

You are about to leave and enter a website operated by a third party.

Would you like to continue?

The information on this site is intended for healthcare professionals in the United States. Are you a healthcare professional in the United States?